MSON - Earnings call transcript Q2 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, everyone, and welcome to the Misonix Second Quarter Fiscal Year 2020 Earnings Call. Today's conference is being recorded.

At this time, I'd like to turn the conference over to Norberto Aja, Investor Relations. Please go ahead.

Norberto Aja

Thank you, operator, and good afternoon, everyone. the XXXX joining call. quarter for you Misonix second fiscal conference Thank get minute a in management's We’ll just comments. with started presentation and doing take me safe so, to before the language. harbor a read disclosure But minute let

similar expect, and guidance will by safe provision to Reform words statements anticipate, the references Act such call meaning Securities and and XXXX results. estimate, U.S. harbor webcast within statements as of statements include Today's Examples the relating future, forward-looking periods. can should, of our of of Private other financial the to likely, may, Litigation contain future be believe, identified forward-looking regarding

Forward-looking to and any circumstances. time, Therefore, statements The future relate of the obligation from of otherwise. future, update any on assurance undertakes be as you statements information, should to they developments changes in whether not to time new historical a publicly are no risks made facts these rely that of are nor future may uncertainties, statements. statements forward-looking to company performance. forward-looking or Because forward-looking subject neither inherent result

and SEC call required, as in G. will as Today's most the reconciliation measures release well non-GAAP financial measures with calculated directly website. accordance a can in financial all to Regulation of non-GAAP When in GAAP press of today's meaning comparable also within the presented the found financial measures webcast the include and company's be

to Misonix. the turn over Please to Mr. CEO Vizirgianakis, ahead. like now call I'd that, go President Stavros With and of

Stavros Vizirgianakis

results. our fiscal on Thank for quarter us review call good the today everyone. afternoon, you, second to and you Norberto, Thank XXXX joining

our on the me call Joining Dwyer, is Joe Chief Officer. Financial today

on of our of particular half prior for periods for for the second our quarter the XX.X% the with first Solsys and and year and fiscal including overall back in first pleased from acquisition. XXXX of half to the second the revenue the the total of improvements fiscal growth strong are growth quarter continue operational results in ability XX% We

year, domestic I'm of forma by wound TheraSkin On forma XX%, by with grew pro growth report a domestic revenue to basis grew pro pleased included international last surgical by X%. revenue revenue grew total for and XX%, revenue sales being XX.X%,

we surgical are sales and product across division. our a results two reminder, separate reporting channels; now our division As our wound

We across and the will We reflects organized that better way the longer no company we acquisition. be have presenting back the consumables results equipment. on the this Solsys of think

a look surgical division. Taking at the

domestic a offering of the revenue increase, reinforces the headed product XX.X% international, excited performance about which I'm pleased the we limited with XX.X% resilience the and Our and Nexus. are opportunities yet ahead. of despite in XX.X% With our rollout direction,

grow our commence we our Nexus As time. a rate to force, larger I'm over and will that at leverage be sales division able of and growth further higher a rollout expand surgical confident

Our positioned sales division this ever with to are the Nexus. resources the before of of better than growth capitalize introduction on

as domestic we confidence growth that division, bring powerful and practitioners. continue care performance, increased availability wound its combination optimize XX% be with compelling health pleased the and pro very the Regarding TheraSkin have further to our forma in increase in to we to revenue a and its SonicOne

is for As that wound sold is fact largely reason U.S. in not small the by a contribution international of the a reminder, the outside TheraSkin driven yet

XXX% geographical forma X.X%. a sales increased basis quick or increased pro a international XX% Domestic from while perspective. healthy look a Taking sales on by by a by

the proceeding clearance the I'm to that our relates approval. it FDA planned and rollout limited by XXX(k) CE on of Nexus, back Mark the receipt as As the to report pleased of is

issues report. are there major We to or no have addressed some minor issues and hiccups

broader move to are ahead we with launch. ready market our So,

Coming to on TheraSkin.

to partner we substitute. allograft cryopreserved both human skin view variety care wounds applications, wounds debridement wound SonicOne, care across its of address all outcomes Our ultrasonic debriding chronic enhance a totality that allows a a and indicated then in for active skin applying patient human TheraSkin by our to practitioners health logical biologically technology as and

to studies clinical coverage TheraSkin additional in private payers. expand amongst investing We're

after an month CryoLife, exclusive announced will closed launching midway shortly NeoPatch we through tissue, deal in which by Solsys full the product, acquisition world year. us leader into commercial later addition, exclusive a about the granting In amniotic we with their rights the to of phase be distribution this we and

down wound Misonix Better around and and as standard-of-care TheraSkin, cementing as EPOS surgical Nexus, building spine, procedural neuro, do support world to us aim the comes and best-in-class we to proprietary the by our Matters. NeoPatch of technology the platform. the submission This solutions across ultrasonic

to underway you significant the a raise. taking the with most Misonix from of see the in integration the Solsys the many to exciting it's place can across initiatives transformative of launching product capital with at to company agreement the CryoLife, really As the the sales recent history changes distribution time force, strategic of our

power for in create doing employees, We customers. our our and drive everything shareholders, to partners, and are value growth

across reps and field the a in to to to between grow regard divisions both our year. and XXX That plan clients. new support have XX now we With and markets surgical, add sales net quarters to to our translates for new sales two five XX we and the quarter per each addressable XX resources next each members divisions; XX over to product team resources, as few domestic of better in wound, look

U.S., remain products, maintain will of presence a deal our in our business, our clients. and small control we we of the in While

and our the driving Looking at pleased continued margin productivity gross reflected initiatives see operations, success on in our of I'm across to as business XX%. on our efficiency focused sales

the making refer Misonix what the to we and with One are Solsys are platform into in creating we progress pleased integrating We Misonix. as

strong through XXXX. Looking ahead, expect the we momentum continue fiscal to

full As such we committed year guidance. our to remain

as sales With projected $XX quarters we increase only well. rate time fiscal for could roughly Solsys' of growth revenue, over sales believe with we three of million XXXX that that the

fiscal company as financial the and continues XXXX whole. across fiscal a so XXXX from summary, our overall In to results trend improvements far of

heading And to R&D, of operations. our our we the by is our further of building to outlook well-positioned on half into Our fiscal and of business. from diversification resources underpinned scale benefit the sales, remain strength constructive, second XXXX the and across continue

With CFO, to would Joe Dwyer. to now I over that, call our Joe? the like turn

Joe Dwyer

afternoon and everyone. you good Stavros thank

As mentioned today's in press release, Solsys Medical. XXth, September on acquired held privately Misonix

acquired ended results Misonix as company's the September as as the period Solsys the Misonix reflect XXst, reported operations Our for reflect from legacy the well as legacy operations well December actual six-month operations. XXXX results XXst. operations The December through XXth Solsys

record increased financial second Fiscal million detail. by million begin our in second to greater with $XX.X the $XX.X of compared last I'll a results year. that reviewing quarter for With product quarter revenue

By basis, coming XX% for The XX.X% a from prior XX.X% a domestic essentially Solsys each gross surgical rise on last geography, On quarter the Misonix sales flat including profit sales wound markets. pro percentage quarter full year, XX% the in at and and in forma international over with of sales the the for current year. XX% second domestic acquired in XX.X% domestic with of a was revenue. for X% of increased had assuming international last quarter revenue revenue was year, from rise compared

primarily million selling increased expenses, expenses, Total year-over-year operating million $XXX,XXX G&A for in million in which Solsys, quarter period. million of includes expenses reflects related and acquisition R&D to of operating $X.X compared $X.X year $X expenses $X.X increase the the to million to expenses. in the another $XX.X The prior in

G&A a we during was Chinese a the addition, which In relating for royalty partner, charge agreement expenses non-cash fully our to to to charged recorded $XXX,XXX reserve contract our quarter. asset with

take Our charge. Chinese minimum this defaulted to royalty XXXX us partner its which on caused December payment

plan does revenue renegotiate Our the not agreement Misonix impact our partner. is both guidance. align to to and charge in the better economics coming benefits Chinese This the our and to months

pro to the acquired Solsys was quarter had the G&A forma of costs, of during excluding approximately or operating salesforce, basis, from in the contract million current acquired quarter XX%. $X.X sales extra newly increase last expenses by million fees, quarter cost $XXX,XXX a the On and asset for of reserve. increased full the $X assuming larger marketing and the for This $X.X from for million the expense Interest second debt. primarily addition compensation consists M&A total costs from year the in Misonix

asset loss reported attributable or to of share reserve. of $X.XX $X.X or period. a $XXX,XXX per in quarter income net and $X The to year-over-year and million decrease compared $X.XX million net share of income a net was year acquisition prior per primarily diluted net loss contract share second Solsys We the the in per the

$X.X We year prior the gain reported of an of $XXX,XXX adjusted EBITDA adjusted EBITDA million compared loss QX in period. to

sometime next year EBITDA report stated and we in we to calls XXXX. on to fiscal Solsys, of with beginning this rest EBITDA be the addition adjusted at positive of As fiscal expect negative for the year prior

in $XX.X cash at cash cash We Moving XX with million December support flow XX debt. million. end about fiscal with second quarter inventory for the operations at due of in $XX at QX Working million We cash about and in XXXX along forma so December added December loss with to cash now was the we to had million used and balance capital for to was build and cash pro million equity of our our use the $X quarter. another to at the $X $XX.X sheet. $XX.X growing in products for $XX.X to raise equity our of demand January increase offering, operating an funding million, of the mainly XX, million ended was approximately

with Solsys' terms. closing expanded $X further while improving sheet our and we capacity, And we strengthened credit terms $XX increased to we assumed you As financing recall million. $XX December million from the the the interest revolving of renegotiated in facility at balance of our term debt million rate and key September to million and borrowing expand debt other our reducing XXXX, secured of $X

be future. in and cash, our expanded debt of positioned million to profitability $XX believe able rapidly operations the our growing facility well to matures we'll debt our service With we're when and fund the that it to we

approximately guidance of consolidated year, we quarters basis fiscal pro of margins for product revenue forma expect us the fiscal XXXX. and three continue With to Regarding on XX% million Solsys for XXXX, a XX% profit growth a gross about growth for rate $XX at at XX%. puts

line our grow a bottom are while on strategies executing and top the and healthy structure. capital we deployed line, to we've preserving follow approach and to balance both we'll integration closing, operating continue successfully In sheet and

including remainder through across our long-term of As our ability meet goal fiscal we and broad verticals value the our remain execute our we productivity enhancing of Nexus as successfully sales wound move we and our beyond. of commencing the market and launch growth to continue to shareholder in initiatives XXXX surgical improving platform,

open Operator? the to like up to I'd call that, questions. With

Operator

Thank Alex Nowak first from Craig-Hallum you. [Operator question Group. Instructions] We'll Capital take our with

Alex Nowak

legacy five months the wound Solsys how since talk about the been then deal? product to wound Great. all all about now Solsys going? is Good team it's new the now product you of picture, since afternoon bigger swapped you market the just forces everyone. just the has you the team? Stavros, wound integration And from completing with And anything Misonix acquisition. the Can closed the surprised at or sales the two is

Stavros Vizirgianakis

thank you that very Alex. much. you Yes, Thank for

are In team. the the towards I quarter. place would the of into product quarter. the end the December SonicOne November, the recent wound accelerated team That It we terms the complete in of from quarter, terms of debridement the wound legacy integration, October, surgical transitioning took say during that

Solsys' year-end As remember, will the you was financial December.

close their chasing the lot a still So are TheraSkin year. essentially numbers people to of

So lessons. I couple is learned the underway. a think well we've of everything And given integration

covered we've is what SonicOne with ground opportunity need accounts think TheraSkin because on that SonicOne of the a people were additional perspective, accounts the dual the with X% TheraSkin. meaning seen from of we was we that that X% only I only is had part SonicOne

people what a think you sit so can longer there first typical as quarter ground cases, cover do additional we case. than because I that seen need you we've know that for So tissue just we around the the some cases in debridement while on a

bit little having essentially additional training a we've feet product was the is just We've what been also is a need pick sales we a there, needed seen has OR-focused bit had where and selling and time got seen think a getting more and comfortable product that in here dropped growth. more is. which force that up business with of a But, where now, has I some it product. accelerate And ground. more know think, just people couple single terms to I we little plans we've selling taken certainly we So, training of a the the on that

that's system the focus the think, and of gates very that's to I needed new well goals aligned with business for the out team but making with only provided the are And, grow tissue go in not number, early what's SonicOne given debridement I January, the people to think, comp to the number, company them aggressively. reach incentivized the and

we're well. So, the integration is think, that I optimistic going

down, think six everything really reasonable bedded is closed because months September. I we to get really a late time

just had completed but months looking good. far we've So it's now, so four

Alex Nowak

that. the that That's last mean, sale you low-hanging what for there and then there? Solsys the point be, with good to that about in overlap could would fruit? just to thinking look to that -- an like? SonicOne X%. easy if years, I'd consider to -- is that being couple And call, that SonicOne Or on you make, rep on just a sell And thoughts Is it of ultimately I at TheraSkin, hear. look my just at the what

Stavros Vizirgianakis

Yes.

think, product easy. of the sell, terms I it is in

are I in have through. spend committees OR back are to we the what time go as more think that the still reality that we there finding the is you

So not in it's bring many just into been it. instances, not the an that's using if account OR, to tissue used it's to easy

we time, in more easier whole just seeing with get our and early successes those the that us for to it our as we I significantly do. But really value that relationships cement will certainly of debridement theory result think, business. of show we're offering, lot combining tissue can validates a over

we're of wins. a the lot early So getting

on that people going get going it's can over build confidence. be It's something think really a accelerates be I as we business more to that time. to

time I big a as to them had of your people the But comfortable. that, get a think that's people business more is some that get little their we've what to to success, well, comfortable as more and that of will point and soon the they have in in of impossible spend longer there. seen, haven't bit it's their as not mission earlier portion an taken see OR, really

that think the that's the real our see bigger big becomes growing will So on drive because is big use complex OR, business towards I an tissue. to able wounds, areas wounds We pieces you're where sales we debride force solution and where that then most in think the valuable. the of value area where these that's

comfortable force bigger and in think that we the wins. think, technology, and of gets we'll with really But, the the segment So get as matures early we'll growth sales that I over business. see more time the bigger

Alex Nowak

where complement And then, where spine sense. that neuro, you have in there makes and like add today you would doing already TheraSkin That SonicOne? product Understood. and SonaStar, a in could BoneScalpel and you're just the product market, with

Stavros Vizirgianakis

Yes.

a from within areas to looked more orientated companies. company a think niche move to spine. number procedurally Obviously, tool a of being I we've of

definitely the the I If think, there're opportunities to look stands in product. neurosurgery, areas things, the a side. we one certainly of at out that add as cranial think, I in side neuro complementary of dural

that be that at. So something look will we

area CryoLife there are we'll a as that complementary areas spine think, variety the announcement, niche I solutions the some fill also. to surgeons. to well, seen opportunities as then, up we've with basically products can bag in we with offer think, And of I continue in that

Alex Nowak

one And question, the there. Understood. then partner Okay. just that you Chinese just quick on mentioned

have well? Just us been XX back. were Chinese also $X payments million, agent? I they the license sales partner manufacturing remind doing while that Were just from last was And in there made us months. know, country. that this the call Chinese just revenue it, much they Or over a did how was a remind the as taking partner come the role

Stavros Vizirgianakis

partner and also going is manufacture. to in does still Yes. -- distribution distribution, Chinese essentially successfully doing was be involved very well, This that is our

still think, in So, that is partnership very the much place. I

what to longer the we've taking I with authorities. do to in agreement, the regulatory think, things get China is had modify because are Chinese registered certainly product

we a expect from least up we support China. being level our running a people to need Operations, terms of saw get up had royalty transfer it what well meant them -- able be We in in payments our January. That without greater to to products. is over and the the to has manufacturing team, provide of engineers onerous that, running, of And manufacture would these say Head in and being perspective, our to tech as royalty to as make

we're essentially in So term months the still to manufactured probably being China away market. XX see for we XX to from think product the have mainly opportunity registered and in Chinese international in an that really we Nexus. market, manufacture on do able nearer and But are resources could product for but because in back market, we to where the focused domestic use all the the in China ship our U.S.

it's had well, that agreement that needs think an agreement the as impact increasing costs. tariffs we an Obviously, some So modification. on

to So with at when strained, a becomes the agreement. you new need profit I think, manufacturer relook

So, in it. it's at we're that I think, something process, looking

will up come the coming solution we'll and months. We engage with the new with in partner a

Alex Nowak

Thank Understood. you. Okay.

Stavros Vizirgianakis

Pleasure.

Operator

we'll next with And Ryan take Zimmerman BTIG.

Ryan Benjamin

guys. good A the a quarter in change here. of Congrats lot Great.

a launch discuss you're implies that with I Just soft can Nexus that the to little Stavros elaborate we from that? or saw One going things. rollout. want then full means what launch I terms would the color what sales full And And few the to you're Can a there approaching How the start on you have you're bit? about your be that How helpful. of Any pipeline? launch? thinking force. follow-up in on a

Stavros Vizirgianakis

Sure.

company's a launching of would of go most in adopted since I after the launch group think we the significant individuals Nexus was that product. headed really the young the we've slowly terms this approach and

December, I said think get went of into evaluation We've really Nexus towards That really the country about get the the targeted. in a learned valuations them trained around we lot close to comfortable, to the slowly. of middle managed being and months. we round So Nexus sites first and them have couple get also phase them that we salesperson of get up, every first

So Nexus quarter ended I units with than consigned more the XX think we handpieces purchased. and

So expectations. the We was in pipeline. a really above being of the number units year that gave XXX for

into confident launch now XXX moving exceed platform as targeted go national up and of We by we've the onto go a this are will now that probably that able June essentially January we right the speed year. being units and to faster

So, are positive. indications so far early

Ryan Zimmerman

I want And then sales Great. ask the productivity. about force to

in one I from anywhere reps XX think adding You're total. to year XX

XXX as think I have two You said divisions. the you between

do That force the the the out and you it math divisions? implied about you've of sales across how bunch productivity think ways. those a of So again split different

You've by looked around put just I'd you're by force the of love by you? productivity the surgical just at But just sales expecting wound. acquisition you of get your it Solsys kind the division. And to thoughts as behind what

Stavros Vizirgianakis

Yes.

I think groups. plan really two a of it's different

what five I have on in the think wound seeing are in team that to been years some position is we that that we four instances. have people

we've excess but $X got So competitor are in in excess million. million, that of a that rates of some productivity more our even $X from territories million-territories than $X handful

quarters we has we goes the the $X.X on there around So got an having time of team. wound more a really million start we're start accurate metrics can putting as mark financial if basis SonicOne. Essentially think I probably because on in quarters at think couple look two average And we the I July. wound of and team in new this year year just

SonicOne wound portfolio. good July pretty we'll into a upside is that by think I So the to as adding feel have what

by end financial is that by end the XXX? person? the metrics of more for you per have XXX We'll number Is to June. year, those it probably the of of So closer

average by also would Nexus. surgical we've than the margin. less team side, say a But pretty that just $X.X a I the significant with million so started team there has is On newer

I number going you wouldn't to So want a again, to that's change dramatically. give

by June, team productivity two to be. think for once whole Nexus, I a the going that to rate indication of had better what selling I'll we've full quarters sales is have U.S.

Ryan Zimmerman

want And to out Joe leave here. enough. I don't then Fair Okay.

material agreement So that that CryoLife Joe ask gross think becomes over more time? of I wanted the impact do we how just to the as margins, on about

Joe Dwyer

currently the margins fairly consistent will we have. be with So what

So a royalty I top and it'd XX% think lower than X% little be pay bit a of that. on we

guidance expect any in start our out would don't rolling fiscal XXXX. We we So have immediate in it XXXX that revenue. fiscal don't

Ryan Zimmerman

much. Thank Okay. the in jump very you I’ll queue.

Joe Dwyer

very Thanks much.

Operator

Kyle to Canaccord. next move Rose We'll Instructions] [Operator with

Kyle Rose

Great. Thank gentlemen. here me you in for fitting

appreciate us handpieces patterns So neuro It that as trying like to Nexus. already. they ordering with from Are the circle units I regarding idea being them both four if as give them placed noted an far wanted of buying XX to contribution. seeing to as back the the applications? orthopedic on you comments could you as Are respect you well seeing I buying also kind those what Just sounds wondered purchased you're for Stavros, understand there. people two handpieces, handpieces? handpieces. just

Stavros Vizirgianakis

Sure. questions. Thanks, Kyle. your Thanks for

is I days system seeing we're think early up. going what every

the going neuro is are evaluations. – are a evaluations XX% is to I we're moment. the approach the our of are we side, that bit customers ordering couple little about neuro we'd of The that lot the first say months these it's And ongoing certainly there's that at units on our there. Roughly the contribution So number's about in a what XX% north think handpieces. modify that we of of two running But how learning out put XX. neuro total at on so XX

I'd over those neuro So seeing that really I add we probably early that think number coming the well. little is out gate. indications base, right that in say now, But are are of total XX% to speed will the of neuro time. handpieces think order And wound-orientated. generally bit a as would and of people just the BoneScalpel handpieces. What I north initial up And is two where

Kyle Rose

if into more had little think are seeing a But historically timing that a account a the evaluations then When you're what insight those you an West I completed Coast large from mentioned evaluation. And of had Okay. you that -- any the seeing, also, from neuro just they evaluations? get maybe can perspective area? you that And decision then you you a when tips a any about turn in chain? are have from in revenues? talk handpieces do supply and supply? the still that on Where you're constraints And to positive, feeling impact on expect

Stavros Vizirgianakis

Sure.

What what on wound evaluation is on BoneScalpel anywhere The a think complete. is evaluations, a to on four the evaluation neuro neuro evaluations you that three the would take the our about seeing So, months I shortest we're competitive six I I weeks neuro say definite longer. a seeing from probably there's trend to we've seems we've side mean we're and spoken be West months. that the completed evaluations. Coast, situation

One of the last of a competitors their literally at starts of the is literally completing two handful in cases. think parts I evaluations

were hoping panned So definitely has a weeks get January, to answer out there. in of And next probably have we'll but the I by we definitive end two hear three before to the we'll everything end February. of how that the think

But because salespeople is helping sales we very side neuro the the adding the field, the in seen got additional was some we've to resources feedback specialist our need space. and the from initial in get neuro comfortable reps, What positive. we've side on people being been to we've the

From a and multiple are spending to spine is we they're two, day. they're what and anywhere cases timing cases, hours idle a more in hours the do definitely or they one six perspective, one more than cases are from in out three salespeople hour whereas lot that the because finding neuro in and around

Misonix the where finding that week. to So BoneScalpel on series longer, of it's not It's a evaluations neuro like certainly cases. try that used technology the they what want done haven't before, with a couple surgeons one within gets and it cases of you're take where

back comfortable Sometimes, time positive. given it's neuro neuro side. our And weeks think that's the the so over as far think but But that you're good will that to arena. on over area, success the the to in people so It's in see I so time coming so multiple far, grows get surgeon. grow I confidence that

terms I three down in the In really units. into console areas supply of chain, terms the of it break

a perspective. we've encouraging. express what outsourced been partner distribution produce from needed has Our That's able demand up very really stood been to and been

unique lot good. there In pressure terms the been just from item had to single What percentage single a sets we of very, for of us, low-single-digits. our have issues pain tips, a That total have we've business seen of line small tips been vendor. that given a packs, one the disposable where we a MIS has little has cooperation a like but bit testing we've the a that on tube a of also process vendors. very and of outsourced has us point some Literally

The handpieces, building are team before, our focused more as handpieces. said existing transitioning we developing I've to and on be

all of the capacity hoping we're back-order to is demand. But look excess first an There capacity. they months, it are from build So meeting in to a if coming at that we have situation.

and of has order I orders think healthiest our of total business But amount every a manageable. the back a revenue even business. certainly small back is really minuscule of portion

quarter we additional of think that built stock. amount have So a seen fair this will you I

gone X it think is has I million? Joe, million, the number X up.

Joe Dwyer

Right, yeah.

Stavros Vizirgianakis

we're think supporting we're certainly legacy So Misonix. is I now, Nexus. we're challenge The not also only right supporting But building capacity.

our all So production we've literally had to double capability.

on So that it's stock the well. But we've months I six shelf. of like not got think done we've

I legacy as continue then momentum, we we'll build think and the can cut starts back Nexus to products. coming some on streamline. And months, more over of getting the

But I I for think point not yet. it's the think control. exactly short answer it pain want is under a we company. no longer where it's It's But

Kyle Rose

Okay. Great more And and then, hop I'll in two me. then, back for queue. questions just

side? to with just wound Joe, you care first The out respect is, components the mix break the can

relative just on quarter underlying that, from consolidated in understand a full the contribution first But wound the SonicOne to we're you're I business? here, basis. mean, I reporting the given Solsys what was

Joe Dwyer

So separately. breaking we're not out wound

of wound at But it's revenue in our we we precise filed, sort million-something on run numbers rate not $X S-X perspective. giving range, the I had look in think that if from a what from the that. probably we're we

Kyle Rose

Okay.

Joe Dwyer

which wound million is So $X.X altogether given for quarter. total the just

Kyle Rose

And just between can housekeeping what wound breakdown sales -- XXX surgical you perspective you've and then, you said was? me Can reps. Okay. remind the a from I think

Stavros Vizirgianakis

at XX, it's exact and on XX Kyle the XXX And on wound number. say is the would Yes. surgical side the side. I

Kyle Rose

thank you very much. Great,

Stavros Vizirgianakis

Pleasure.

Operator

That this of portion over closing for concludes back will turn call. I the remarks. Q&A the management At call time, the to

Stavros Vizirgianakis

and with your a I'd this for participation a to and for talented call. in you in extremely the operator, members thank you contributions dedicated you you, team placed Thank confidence to your thanks to special afternoon's Misonix to and take the extend all company. everyone world-class make thank like opportunity for their to investment us this

arise or report the interim later firm you forward please to look XXXX a Investor contact (XXX) if at JCIR, quarter management, this you'd our we results, with fiscal schedule speaking We third to with year. Relations in like additional when XXX-XXXX. meeting any questions again, formal Should

Thank and goodbye. you

Operator

That for you. your conference today. our do you for Thank participation. We conclude call does thank

You disconnect. may now

Misonix (MSON) 5 Feb 202020 Q2 Earnings call transcript